Momenta Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc.

MNTA 52.48

0.0%

Oct 2 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ian@SI who wrote (2481)	9/7/2010 4:14:00 PM
From: tuck	of 3027

I don't think the IMS data even reflects major hospital contracts, at least not entirely. Does not capture non-prescription use in the surgical setting, for example. I think SNY does still have a commanding lead in share there. It's more the outpatient, retail level that Sandoz is penetrating at the moment. There have been anecdotal discussions of contracts with GPOs and hospitals and such on IHub, but there isn't enough information to be very illuminating at this point. Further, long term contracts for the branded do not necessarily mean that the generic won't be used, and there are generally cancellation clauses involving 30 days notice from the buyer. At least that's my understanding. If anyone has further info, color, or corrections I am humbly all ears. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next